Dynamic quotes: Off
|
Company Description (as filed with the SEC)
SciClone Pharmaceuticals (NASDAQ: SCLN) is a revenue-generating, profitable, United States (“US”)-based, China-focused, specialty pharmaceutical company with a substantial commercial business and a product portfolio of therapies for oncology, infectious diseases, cardiovascular, urological, respiratory and central nervous system disorders. We are focused on continuing to grow our revenue and profitability through our strong sales and marketing efforts. Our business and corporate strategy is focused primarily on the People’s Republic of China (“China”) where we have built a solid reputation and established a strong brand through many years of experience marketing our lead product, ZADAXIN (thymalfasin). In addition, we have an established product promotion business model with large pharmaceutical partners and we are focused on establishing profitability in all of these collaborations. ... More ...
Analyst Info |
|
| Annual EPS Est: | $0.56 |
| Quarterly EPS Est: | 0.02 |
| PEG Ratio: | .01 |
|
Mean Recommendation: View Summary / View All |
2 |
Data is provided by Zacks Investment Research

